首页> 美国卫生研究院文献>Nutrients >The Effect of Birch Pollen Immunotherapy on Apple and rMal d 1 Challenges in Adults with Apple Allergy
【2h】

The Effect of Birch Pollen Immunotherapy on Apple and rMal d 1 Challenges in Adults with Apple Allergy

机译:桦木花粉免疫疗法对苹果过敏成人苹果和rMal d 1挑战的影响

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background: A proportion of patients allergic to birch pollen are also allergic to pit fruit. The objective of this study was to investigate the effect of immunotherapy with birch pollen on birch-pollen-related apple allergy. Method: Patients with birch pollen immunotherapy underwent a skin-prick test with birch pollen, apple and rMal d 1, global assessments and nasal challenges with birch pollen, open food challenge with apple and a double-blind, placebo-controlled test with rMal d 1 at the start of and during the immunotherapy. Measurements of specific IgE in response to Bet v 1 and rMal d 1 and IgG4 in response to Bet v 1 and rMal d 1 took place. Results: Six of eight patients demonstrated an improvement of nasal challenge test results and all patients improved on global assessment during the immunotherapy. The median oral dose of apple required to elicit a reaction increased but was not statistically significant. The patients showed a decrease in skin-prick test values in response to birch pollen (1.05 to 0.36), apple (0.78 to 0.25) and rMal d 1 (0.51 to 0.10) with -values of 0.04, 0.03 and 0.06, respectively and a decrease of specific IgE in response to Bet v 1 (10.66 kU/L to 5.19 kU/L) and rMal d 1 (0.99 to 0.61 kU/L) with -values of 0.01 and 0.05, respectively. Only the median specific IgG4 value to Bet v 1 increased from 0.05 to 1.85 mg/L ( -value of 0.02) and not to IgG4 rMal d 1 (0.07 to 0.08 kU/L). Conclusion: The beneficial effects of immunotherapy for birch pollen were accompanied by a limited effect on apple allergy.
机译:背景:对桦木花粉过敏的患者中有一部分对果皮过敏。这项研究的目的是调查桦木花粉免疫疗法对桦木花粉相关的苹果过敏的影响。方法:桦树花粉免疫疗法的患者接受了桦树花粉,苹果和rMal d的皮肤点刺试验d 1,全球评估和桦树花粉的鼻挑战,苹果的开放式食物挑战以及rMal d的双盲,安慰剂对照试验免疫治疗开始时和免疫治疗期间为1。测量了响应于Bet v 1和rMal d 1的特异性IgE和响应于Bet v 1和rMal d 1的IgG4。结果:八名患者中有六名表现出鼻激发试验结果的改善,并且所有患者在免疫治疗过程中的总体评估均有改善。引起反应所需的苹果中位口服剂量增加,但无统计学意义。患者对桦木花粉(1.05至0.36),苹果(0.78至0.25)和rMal d 1(0.51至0.10)的皮肤点刺测试值降低,其中-值分别为0.04、0.03和0.06,a响应于Bet v 1(10.66 kU / L至5.19 kU / L)和rMal d 1(0.99至0.61 kU / L)而降低的特异性IgE的-值分别为0.01和0.05。仅Bet v 1的中值特异性IgG4值从0.05增至1.85 mg / L(-值为0.02),而不是IgG4 rMal d 1增高(0.07至0.08 kU / L)。结论:桦木花粉免疫治疗的有益作用是对苹果过敏的有限作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号